Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

With Colorectal Cancer: Knowledge is Power

We support cancer research and awareness because the global burden is unacceptable. There are an estimated 18,000,000 new cases diagnosed each year, and 9,500,000 people who lost their battle with cancer worldwide.1

According to the International Agency for Research on Cancer (IARC), colorectal cancer is the third most common cancer worldwide and the second most common cause of cancer death; approximately 880,000 people around the globe will lose their battle with colorectal cancer each year.1,2

Colorectal cancer is unique in that it is one of the most preventable, and if found early, most treatable forms of cancer. Knowing your personal medical history, including Lynch syndrome status, is key.

Promega employees wear blue and join the fight against colorectal cancer

Promega employees wear blue in March 2020 to join the fight against colorectal cancer.

Partnering Together

Colon Cancer Coalition Logo

In partnership with the Colon Cancer Coalition, join us during the month of May 2021 for the Get Your Rear in Gear (GYRIG) fun virtual event. Run, walk or ride while raising funds and awareness for colorectal cancer.

Join us for the Get Your Rear in Gear (GYRIG) fun virtual event.

Register early to get a T-shirt. Free registration for colorectal cancer patients and survivors.

Putting Your Support into Action

Over the last two years, people have joined the fight against colorectal cancer by responding to our call to take a pledge to get screened, learn about their family health history, talk to friends and family about colorectal cancer or wearing blue for CRC month.

For each pledge in 2020, we donated $10 to support Fight Colorectal Cancer's Call-On Congress campaign, a three-day event that supports survivors, caregivers and loved ones impacted by colorectal cancer to make their voices heard by governing bodies in the United States. In 2019, each pledged earned a donation towards the funding of a Research Advocacy Training and Support(RATS) program, hosted by Promega. As part of this program, ten survivors, caregivers and colorectal cancer champions were trained on the science behind colorectal cancer, becoming well-versed voices that can effectively engage with researchers, academic institutions and cancer partners in the scientific community.

Meet Stacy and hear her story.

“This is where the patient experience is going: more collaboration among advocates, industry, and health care providers.” — Stacy Hurt, Stage IV colorectal cancer survivor turned colon cancer advocate and educator for the RATS program

Surveillance and Early Detection Saves Lives

Colorectal cancer is the third most common cancer and the second most common cause of cancer death worldwide.1,2

Despite its high incidence, colorectal cancer is unique in that it is one of the most preventable and, if found early, most treatable forms of cancer. Knowing your personal medical history, including Lynch status, can help you and your family members make better informed decisions.

Local Stage

Cancer has grown into but not extended through colon wall.

Regional Stage

Cancer has spread through colon wall to nearby tissue or to nearby lymph nodes.

Distant Stage

Cancer has spread to other parts of the body.

Five Year Survival Rates Based on Disease Stage at Diagnosis2

Colorectal cancer survival rates

Every Patient has a Story

Carrie Ketcham, Diagnosed at 49

Carrie Ketcham is a mother of two who had her first cancer diagnosis in 2009 at age 44. Five years later she was diagnosed with the hereditary condition, Lynch syndrome, after being diagnosed with colorectal cancer.

“…part of why I went through [this] is because I didn’t know. Your knowledge is powerful, it’s gonna keep you healthy and safe” — Carrie Ketcham, Lynch Syndrome Patient

Read Carrie’s Story

Lynch Syndrome testing advocate Carrie Ketcham


Mike Dampf, Diagnosed at 37

Mike Dampf is a father of two who was diagnosed with colon cancer and Lynch syndrome in 2010 at the age of 37.

“Lynch is different. Education is key. You need to get as smart as you can. Good doctors will understand it, but you also need to do your own research. You can’t just sit back and wait.”

Read Mike's Story

Do You Know Your Risk?

As many as 1 in 279 people might be carriers for the mutations associated with Lynch syndrome.3 A family history of an immediate family member (parent or sibling) or multiple family members with colorectal cancer or polyps puts you at an increased risk for the disease. Knowing your risk can help you and your healthcare professional make better, more informed decisions about your health before the onset of cancer or before a second cancer has had a chance to develop.

Genetics of Inherited Colorectal Cancer

In some families, cancer occurs more often than expected. A family history of colorectal cancer can suggest a genetic factor. There are two genetic syndromes associated with colorectal cancer, Familial Adenomatous Polyposis and Lynch syndrome.

Familial Adenomatous Polyposis

Familial Adenomatous Polyposis (FAP) results from autosomal dominant mutations in the tumor suppressor gene, APC, and causes approximately 1% of all colon cancers. Most people develop multiple colon polyps by the age 39. If not detected and treated, these polyps will almost always develop into cancer. Typically FAP is diagnosed when your doctor finds a large number (>100) of colorectal polyps. Blood tests can be used to confirm the presence of mutations associated with FAP.4

Lynch Syndrome

Lynch syndrome, or hereditary nonpolyposis colon cancer, is the most common form of hereditary colorectal cancer and causes roughly 3-5% of all colon cancers.5 Lynch syndrome is caused by autosomal dominant mutations to the major mismatch repair genes MLH1, MSH2, MSH6 or PMS2 as well as the EPCAM gene that inactivates MSH2. In addition to colorectal cancer, Lynch syndrome is associated with several other cancers including endometrial, ovarian and stomach cancer.

Autosomal Dominant Inheritance Pattern

Autosomal dominant inheritance pattern

Why is it important to know your Lynch Status?

In addition to colorectal cancer, people with Lynch syndrome have an increased lifetime risk of developing certain other cancers. Because it is an inherited condition, family members might also have the condition.

“The worst part about Lynch is how many people don’t know they have it until they have cancer. If somewhere along the way it was tested…you know, a person could be spared.” – Carrie Ketcham, Lynch Syndrome Patient

Representative Lifetime Cancer Risk Comparison in the United States


How Is Lynch Syndrome Diagnosed?

To determine if Lynch syndrome is likely, simple screening tests can be performed on tumor (cancer) tissue. The two most common tests are microsatellite instability testing (MSI) and immunohistochemistry testing (IHC) for mismatch repair proteins (MMR). The results of these tests can indicate whether more specific genetic testing should be considered.

Lynch Syndrome and MSI

High microsatellite instability (MSI-H) in tumor tissue is a hallmark of Lynch syndrome. MSI-H status indicates that certain sections of DNA called microsatellites have become unstable because the major mismatch repair genes that correct errors during DNA replication are not functioning properly. A DNA analysis test is used to determine MSI status. The test is performed on both normal and tumor tissue. If the results for the tumor differ from the normal tissue results, the tumor is considered MSI-H.

Lynch Syndrome and IHC

Immunohistochemistry is a screening test for Lynch syndrome tumors that looks for the proteins expressed by the mismatch repair (MMR) genes. If the genes are functioning properly, the proteins will be present. Absence of a mismatch repair protein increases the likelihood that Lynch syndrome is present.

Living with Lynch

Early detection and diagnosis of Lynch syndrome can significantly change a patient's life. In 2019, Promega supported the partnership between the Colon Cancer Coalition and AliveAndKickn to share the inspiring stories of Living with Lynch Advocates.

“I can honestly say that being diagnosed with Lynch syndrome really saved my life.” — Amber, Colon and Ovarian Cancer Survivor, Lynch syndrome Positive

Hear the Stories

The Value of Screening Every Tumor for Microsatellite Instability

Universal screening of all tumors and Lynch-associated cancers could help identify patients and families who have an increased risk for colorectal and other cancers. Screening can also identify tumors most likely to respond to immunotherapeutics.

Genetic counselor Heather Hampel is an advocate for universal tumor screening for Lynch syndrome.

Read the Article


“…you have tumor tests you can use to identify the patients that are more likely to have it […] And you have surveillance that really works” — Heather Hampel, MS, LGC, The Ohio State University

The Research Never Stops…

Exploring data, asking questions and posing new theories that will help us understand the how and why of the way things work. Because, ultimately, research is what leads to prevention, treatments and cures.

Knowledge is power.


1Pan American Health Organization/World Health Organization Accessed February 11, 2021. Coloreactal Cancer Statistics Accessed February 11, 2021.
3Win, A. K. et al. (2017) Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol. Prev. 26, 404–12.
4MedlinePlus. Familia Adenomatous Polyposis Accessed February 11, 2021. Lynch Syndrome Accessed February 11, 2021. Lifetime Risk of Developing or Dying from Cancer Accessed February 11, 2021.